Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to ABT-335 and rosuvastatin calcium monotherapy in subjects with mixed dyslipidemia

X
Trial Profile

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to ABT-335 and rosuvastatin calcium monotherapy in subjects with mixed dyslipidemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Choline fenofibrate (Primary) ; Rosuvastatin (Primary)
  • Indications Dyslipidaemias; Lipid metabolism disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 08 Jun 2009 Results of a retrospective analysis were presented at the 69th annual meeting of the American Diabetes Association, according to a Abbott Laboratories media release.
    • 03 Jun 2008 Primary endpoints all met. Results presented at the American Society of Clinical Oncology (ASCO) 2008.
    • 02 Jun 2008 Results data have been reported at the National Lipid Association 2008 meeting and in a media release from Abbott.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top